On January 22, 2026 PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, reported the closing of a Series B extension, bringing the company’s total Series B financing to $77 million, and the dosing of the first patient in a Phase 1 clinical trial evaluating PT0511, the company’s pan-KRAS degrader.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Series B extension builds on PAQ’s previously announced Series B financing, with participation from existing as well as new investors, and further strengthens the company’s balance sheet to advance multiple clinical programs. Proceeds from the financing will support the ongoing Phase 1 development of PT0253, PAQ’s KRAS G12D degrader, as well as the clinical advancement of PT0511.

"Completing this Series B extension and dosing the first patient in our PT0511 Phase 1 study represent important milestones for PAQ," said Nan Ji, PhD, Chief Executive Officer of PAQ Therapeutics. "Together, these achievements highlight our continued execution against a multi-program clinical strategy and our focus on addressing significant unmet need across KRAS-driven cancers."

PT0511 is a pan-KRAS degrader designed to target multiple oncogenic KRAS variants. The Phase 1 study is a first-in-human, open-label, dose-escalation trial evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of PT0511 in patients with advanced solid tumors harboring KRAS alterations.

"The initiation of clinical dosing with PT0511 expands our clinical portfolio beyond single-mutation KRAS targeting," said Andrew Krivoshik, MD, PhD, Chief Medical Officer of PAQ Therapeutics. "A pan-KRAS degradation approach has the potential to address key limitations for patients observed with existing KRAS- or pan-RAS inhibitor therapies."

PAQ continues to advance a differentiated KRAS pipeline by leveraging targeted protein degradation to achieve deep and selective suppression of oncogenic signaling, while maintaining favorable safety and combinability profiles.

(Press release, PAQ Therapeutics, JAN 22, 2026, View Source [SID1234662174])

On January 22, 2026 Israel Cancer Research Fund (ICRF) and the Cancer Research Institute (CRI) reported to have partnered on a new award, the ICRF-CRI Immunotherapy Collaborative Project Grant, given to Dr. Asaf Madi, PhD, of Tel Aviv University. Dr. Madi was awarded $180,000 over a three-year period to support his research on refining tumor-infiltrating lymphocyte (TIL) therapy to predict response and overcome drug resistance in melanoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored to once again partner with CRI, a world-class immunotherapy research organization, on this cutting-edge project," said Alan Herman, ICRF’s Executive Director. "There is a clear, unmet need for personalized treatments like TIL therapy, and Dr. Madi’s research into adoptive cell transfer could offer new hope to melanoma patients in urgent need of better options."

Adoptive cell transfer (ACT) using TILs is a promising personalized immunotherapy for melanoma, shown to improve survival in advanced cases. However, many patients do not respond, and others develop resistance, limiting the long-term effectiveness of this approach. Dr. Madi’s research aims to address these challenges by identifying predictive biomarkers, uncovering mechanisms of tumor resistance, and optimizing TIL selection and expansion to improve therapeutic outcomes.

Dr. Madi and his team are studying the gene circuits that program immune cells, controlling their differentiation, activation, and regulation. By examining how T cells behave in tumors, particularly following immunotherapy, they aim to determine why some T cells sustain anti-tumor activity while others become exhausted or suppressed. Insights from this work will guide the selection and engineering of more potent TIL populations capable of durable tumor targeting and generating long-term immune memory, reducing the risk of cancer recurrence.

"This collaboration reflects what progress in immunotherapy really looks like—bringing together partners, data, and discovery to tackle resistance head-on," said Alicia Zhou, PhD, CEO of CRI. "By understanding why some immune cells persist while others fail, Dr. Madi’s work moves us closer to making personalized cell therapies like TILs more reliable, more durable, and more transformative for patients with melanoma."

Melanoma is the deadliest form of skin cancer. In the U.S. alone, over 100,000 new cases are diagnosed each year, and advanced melanoma can be resistant to standard treatments. Because it can spread quickly and evade therapies, developing new, effective treatments is critical to improve survival and offer hope to patients and their families worldwide.

Dr. Asaf Madi earned his Ph.D. in computational immunology at Tel Aviv University in collaboration with the Weizmann Institute of Science, studying B cell and T cell repertoires. He then completed a postdoctoral fellowship at Harvard Medical School and the Broad Institute, focusing on T-cell differentiation and cancer immunology. Dr. Madi then returned to Tel Aviv University, where he is now an Associate Professor in the Department of Pathology, leading a team that drives the development of novel anti-cancer therapies.

(Press release, Cancer Research Institute, JAN 22, 2026, View Source [SID1234662175])

On January 22, 2026 CorriXR Therapeutics, an oncology focused biotherapeutics company developing genetic medicines to overcome drug resistance in solid tumors, reported that its novel CRISPR-directed disruption of the transcription factor NRF2 can restore chemosensitivity in head and neck and esophageal squamous cell carcinoma models. The preclinical data were published in Molecular Therapy Oncology. The study, conducted in collaboration with scientists at ChristianaCare’s Gene Editing Institute (GEI), reinforces CorriXR’s previously reported data in lung cancer models and highlights how CRISPR targeting of NRF2 can disrupt tumor cells’ protective mechanisms and potentially boost patients’ bodies’ ability to respond more effectively to standard chemotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For patients with solid tumor cancers, once their tumors become resistant to chemotherapy, treatment options narrow and are often more toxic to them," said Eric B Kmiec, Ph.D., Founder and Chief Executive Officer of CorriXR Therapeutics and Executive Director of GEI. "These data from CorriXR’s first-in-class editing approach suggest that by precisely disrupting NRF2, we may be able to reopen the window to standard treatments and potentially do so at lower doses; this could translate into better control of disease with fewer side effects for patients."

NRF2 is a master regulator of cellular stress responses and a well-established driver of treatment resistance in multiple cancers, making it an attractive but historically "undruggable" target for therapeutic intervention. CorriXR is advancing essential studies to support an IND filing in head and neck squamous cell carcinoma (HNSCC) as a potential first clinical indication.

Head and neck cancer, 90% of which is HNSCC, is the seventh most diagnosed cancer worldwide, with annual incidence predicted to reach one million new cases by 2030. With 50% of patients experiencing recurrence within two years, there is a significant need for new approaches that can overcome resistance to current treatment paradigms. CorriXR anticipates completion of additional in vivo studies in HNSCC in combination with chemotherapy and radiation in the first half of 2026.

Study Overview

Researchers used CRISPR/Cas9 complexes to disrupt NRF2 in hypopharyngeal (FaDu) and esophageal (KYSE‑410) squamous cell carcinoma cells and then assessed gene editing outcomes, NRF2 pathway activity, and response to cisplatin and 5‑fluorouracil. Key study findings include:

High levels of on-target editing produced substantial reductions in NRF2 protein levels, decreased expression of downstream stress response genes, and significantly restored chemosensitivity.
Genetic disruption of NRF2 alone is sufficient to disrupt its ability to activate the genes that defend tumor cells.
Enhanced chemosensitivity after NRF2 disruption persisted over time, creating a treatment window for combination therapy.
The choice of CRISPR editing site on NRF2 influences both the functional impact on NRF2 and which cells are affected by the edit. Editing that disrupts a functional binding domain enables an approach that is agnostic to and independent of genetic mutations in the cancer cells.
"These findings complement previously published data from CorriXR and GEI showing that tumor-specific NRF2 editing in lung cancer models can resensitize tumors to standard chemotherapy and reduce tumor growth in vivo, thereby reinforcing NRF2 as a central node for overcoming drug resistance," said Natalia Rivera-Torres, Ph.D., lead author of the study and Associate Director of Research at GEI.

Kmiec added, "What is most encouraging about this work is that we are giving existing drugs a second chance to work in tumors that have learned how to evade them, enabling patients to benefit more, and longer, from proven regimens, with a better quality of life."

(Press release, CorriXR Therapeutics, JAN 22, 2026, View Source [SID1234662176])

On January 22, 2026 Abbott (NYSE: ABT) reported financial results for the fourth quarter ended Dec. 31, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fourth-quarter sales increased 4.4 percent on a reported basis, 3.0 percent on an organic basis, or 3.8 percent when excluding COVID-19 testing-related sales1.
Fourth-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.50, which excludes specified items and reflects growth of 12 percent.
Full-year 2025 sales of $44.3 billion increased 5.7 percent on a reported basis, 5.5 percent on an organic basis, or 6.7 percent when excluding COVID-19 testing-related sales2.
Full-year 2025 GAAP diluted EPS of $3.72 and adjusted diluted EPS of $5.15, which excludes specified items and reflects growth of 10 percent.
Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.
Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects growth of 10 percent at the midpoint.
In November, Abbott announced an agreement to acquire Exact Sciences, a move that will position the company to enter and lead in the fast-growing cancer diagnostics market. Abbott continues to expect the transaction to close in the second quarter of 2026.
Abbott expanded its leadership in Electrophysiology with two significant regulatory approvals:
In December, Abbott announced U.S. Food and Drug Administration (FDA) approval for its Volt PFA System, bringing Abbott’s first pulsed field ablation (PFA) offering to patients in the United States.
In January, Abbott announced the company obtained CE Mark for its TactiFlex Duo Ablation Catheter, Sensor Enabled, designed to deliver radiofrequency (RF) and PFA energy to treat patients battling atrial fibrillation.
"In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future," said Robert B. Ford, chairman and chief executive officer, Abbott. "We’re well positioned for accelerating growth in 2026."

FOURTH-QUARTER BUSINESS OVERVIEW

Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Fourth Quarter 2025 Results (4Q25)

Sales 4Q25 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

4,383

806

967

—

2,605

International

7,076

1,134

1,490

1,382

3,070

Total reported

11,459

1,940

2,457

1,382

5,675

% Change vs. 4Q24

U.S.

0.9

(13.2)

(8.4)

n/a

10.7

International

6.7

(5.6)

1.8

9.0

13.7

Total reported

4.4

(8.9)

(2.5)

9.0

12.3

Impact of foreign exchange

1.4

0.2

1.1

2.0

1.9

Organic

3.0

(9.1)

(3.6)

7.0

10.4

Impact of COVID-19 testing sales 1

(0.8)

—

(3.4)

—

—

Organic (excluding COVID-19 tests)

3.8

(9.1)

(0.2)

7.0

10.4

Organic

U.S.

0.9

(13.2)

(8.4)

n/a

10.7

International

4.3

(5.9)

(0.2)

7.0

10.1

Full-Year 2025 Results (12M25)

Sales 12M25 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

17,126

3,606

3,535

—

9,968

International

27,202

4,845

5,402

5,536

11,419

Total reported

44,328

8,451

8,937

5,536

21,387

% Change vs. 12M24

U.S.

4.9

(2.3)

(7.7)

n/a

13.4

International

6.1

2.6

(2.0)

6.6

12.0

Total reported

5.7

0.4

(4.3)

6.6

12.6

Impact of foreign exchange

0.2

(0.7)

0.2

(0.8)

0.7

Impact of business exit*

—

(0.1)

—

—

—

Organic

5.5

1.2

(4.5)

7.4

11.9

Impact of COVID-19 testing sales 2

(1.2)

—

(4.9)

—

—

Organic (excluding COVID-19 tests)

6.7

1.2

0.4

7.4

11.9

Organic

U.S.

5.0

(1.9)

(7.7)

n/a

13.4

International

5.9

3.7

(2.3)

7.4

10.5

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.

*Reflects the impact of discontinuing the ZonePerfect product line in the Nutrition business in March 2024.

Nutrition

Fourth Quarter 2025 Results (4Q25)

Sales 4Q25 ($ in millions)

Total

Pediatric

Adult

U.S.

806

463

343

International

1,134

439

695

Total reported

1,940

902

1,038

% Change vs. 4Q24

U.S.

(13.2)

(17.7)

(6.3)

International

(5.6)

0.3

(8.9)

Total reported

(8.9)

(9.8)

(8.1)

Impact of foreign exchange

0.2

0.3

0.1

Organic

(9.1)

(10.1)

(8.2)

U.S.

(13.2)

(17.7)

(6.3)

International

(5.9)

(0.3)

(9.1)

Worldwide Nutrition sales decreased 8.9 percent on a reported basis and 9.1 percent on an organic basis in the fourth quarter.

Results in the quarter reflect the impact of lower sales volumes compared to the prior year and new strategic price actions targeted to increase volume growth in the future. In addition to these strategic price actions, Abbott expects to increase volume growth with the launch of several new products in 2026.

Full-Year 2025 Results (12M25)

Sales 12M25 ($ in millions)

Total

Pediatric

Adult

U.S.

3,606

2,158

1,448

International

4,845

1,816

3,029

Total reported

8,451

3,974

4,477

% Change vs. 12M24

U.S.

(2.3)

(2.3)

(2.2)

International

2.6

0.1

4.1

Total reported

0.4

(1.2)

2.0

Impact of foreign exchange

(0.7)

(0.5)

(0.7)

Impact of business exit*

(0.1)

—

(0.3)

Organic

1.2

(0.7)

3.0

U.S.

(1.9)

(2.3)

(1.4)

International

3.7

1.3

5.1

*Reflects the impact of discontinuing the ZonePerfect product line in the Nutrition business in March 2024.

Diagnostics

Fourth Quarter 2025 Results (4Q25)

Sales 4Q25 ($ in millions)

Total

Core Laboratory

Molecular

Point of Care

Rapid Diagnostics

U.S.

967

376

39

107

445

International

1,490

1,085

102

51

252

Total reported

2,457

1,461

141

158

697

% Change vs. 4Q24

U.S.

(8.4)

3.6

2.9

6.5

(19.7)

International

1.8

5.9

3.3

9.8

(14.1)

Total reported

(2.5)

5.3

3.2

7.5

(17.8)

Impact of foreign exchange

1.1

1.7

2.1

0.4

0.3

Organic

(3.6)

3.6

1.1

7.1

(18.1)

U.S.

(8.4)

3.6

2.9

6.5

(19.7)

International

(0.2)

3.6

0.4

8.3

(14.9)

Global Diagnostics sales decreased 2.5 percent on a reported basis, decreased 3.6 percent on an organic basis, and decreased 0.2 percent when excluding COVID-19 testing-related sales1.

COVID-19 testing-related sales were $89 million in the quarter, compared to $176 million in the fourth quarter of the prior year.

Global Core Laboratory Diagnostics sales increased 5.3 percent on a reported basis and increased 3.6 percent on an organic basis. Growth in other geographies was partially offset by challenging market conditions in China, including the impact of volume-based procurement programs.

Full-Year 2025 Results (12M25)

Sales 12M25 ($ in millions)

Total

Core Laboratory

Molecular

Point of Care

Rapid Diagnostics

U.S.

3,535

1,425

150

422

1,538

International

5,402

3,935

367

184

916

Total reported

8,937

5,360

517

606

2,454

% Change vs. 12M24

U.S.

(7.7)

7.0

0.4

3.4

(20.8)

International

(2.0)

0.8

(1.1)

2.5

(13.3)

Total reported

(4.3)

2.4

(0.7)

3.1

(18.1)

Impact of foreign exchange

0.2

0.3

0.5

—

(0.1)

Organic

(4.5)

2.1

(1.2)

3.1

(18.0)

U.S.

(7.7)

7.0

0.4

3.4

(20.8)

International

(2.3)

0.4

(1.8)

2.4

(13.1)

Established Pharmaceuticals

Fourth Quarter 2025 Results (4Q25)

Sales 4Q25 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

1,382

1,046

336

Total reported

1,382

1,046

336

% Change vs. 4Q24

U.S.

n/a

n/a

n/a

International

9.0

10.3

5.0

Total reported

9.0

10.3

5.0

Impact of foreign exchange

2.0

1.6

3.1

Organic

7.0

8.7

1.9

U.S.

n/a

n/a

n/a

International

7.0

8.7

1.9

Established Pharmaceuticals sales increased 9.0 percent on a reported basis and 7.0 percent on an organic basis in the fourth quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 10.3 percent on a reported basis and 8.7 percent on an organic basis, led by double-digit growth in India and several countries across Latin America and the Middle East.

Full-Year 2025 Results (12M25)

Sales 12M25 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

5,536

4,167

1,369

Total reported

5,536

4,167

1,369

% Change vs. 12M24

U.S.

n/a

n/a

n/a

International

6.6

8.0

2.5

Total reported

6.6

8.0

2.5

Impact of foreign exchange

(0.8)

(1.5)

1.1

Organic

7.4

9.5

1.4

U.S.

n/a

n/a

n/a

International

7.4

9.5

1.4

Medical Devices

Fourth Quarter 2025 Results (4Q25)

Sales 4Q25 ($ in millions)

Total

Rhythm
Management

Electro-

physiology

Heart
Failure

Vascular

Structural
Heart

Neuro-
modulation

Diabetes
Care

U.S.

2,605

340

340

283

287

304

208

843

International

3,070

365

390

92

496

371

66

1,290

Total reported

5,675

705

730

375

783

675

274

2,133

% Change vs. 4Q24

U.S.

10.7

12.8

13.1

11.7

6.5

4.8

1.9

14.9

International

13.7

13.4

13.9

17.9

8.9

16.3

23.8

14.2

Total reported

12.3

13.1

13.5

13.2

8.0

10.8

6.5

14.5

Impact of foreign exchange

1.9

1.6

1.0

1.1

1.5

2.1

0.9

2.8

Organic

10.4

11.5

12.5

12.1

6.5

8.7

5.6

11.7

U.S.

10.7

12.8

13.1

11.7

6.5

4.8

1.9

14.9

International

10.1

10.2

11.9

13.4

6.6

12.3

19.6

9.6

Worldwide Medical Devices sales increased 12.3 percent on a reported basis and 10.4 percent on an organic basis in the fourth quarter.

Sales growth in the quarter was led by double-digit growth in Electrophysiology, Heart Failure, Diabetes Care, and Rhythm Management.

In Diabetes Care, sales of continuous glucose monitors were $2.0 billion and grew 15.0 percent on a reported basis and 12.2 percent on an organic basis.

Full-Year 2025 Results (12M25)

Sales 12M25 ($ in millions)

Total

Rhythm
Management

Electro-

physiology

Heart
Failure

Vascular

Structural
Heart

Neuro-
modulation

Diabetes
Care

U.S.

9,968

1,334

1,283

1,107

1,118

1,172

773

3,181

International

11,419

1,315

1,481

341

1,877

1,351

237

4,817

Total reported

21,387

2,649

2,764

1,448

2,995

2,523

1,010

7,998

% Change vs. 12M24

U.S.

13.4

15.7

12.4

12.2

5.8

11.5

0.8

20.8

International

12.0

6.4

11.7

16.4

5.4

13.0

21.5

15.4

Total reported

12.6

10.9

12.0

13.2

5.6

12.3

5.0

17.5

Impact of foreign exchange

0.7

0.7

0.4

0.5

0.5

0.8

0.2

1.2

Organic

11.9

10.2

11.6

12.7

5.1

11.5

4.8

16.3

U.S.

13.4

15.7

12.4

12.2

5.8

11.5

0.8

20.8

International

10.5

5.0

10.9

14.3

4.7

11.5

20.5

13.5

(Press release, Abbott, JAN 22, 2026, View Source [SID1234662161])

On January 22, 2026 Ellipses Pharma Limited ("Ellipses"), a clinical-stage oncology drug development company with a pipeline of innovative programmes, reported that it has entered into a collaboration and licence agreement with Innolake Biopharm Co. Ltd ("Innolake") to develop a clinical stage first-in-class antibody drug conjugate (ADC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the partnership, Ellipses gains rights to develop a B7H3 targeted ADC with an eribulin payload (ILB-3101) worldwide excluding greater China. ILB-3101 has the potential to treat multiple tumour types and to address resistance to topoisomerase-1 based ADCs. ILB-3101 is designated as EP0028 by Ellipses.

Ellipses and Innolake will collaborate closely on the development of ILB-3101/EP0028, which is currently in a Phase 1 trial in China sponsored by Innolake. Ellipses will initiate a Phase 1 clinical trial in the US with expansion to Europe and other territories following relevant regulatory approvals.

EP0028 is an important addition to Ellipses’ clinical-stage pipeline and is the second programme Ellipses has in-licensed from an innovative biotech company based in China. The first programme, EP0031, is a next-generation selective RET inhibitor developed by Kelun Biotech, which Ellipses is currently advancing through Phase 2 trials.

Professor Sir Chris Evans, OBE, Executive Chair of Ellipses, commented: "We are delighted to bring this differentiated ADC into our pipeline. EP0028 has the potential to address unmet needs in a range of indications and further strengthens our strategy to develop Chinese originated assets in the West."

Professor Tobias Arkenau, Global Head of Drug Development and Chief Medical Officer of Ellipses, commented: "Ellipses’ decision to in-license EP0028 is a significant milestone for us in continuing our mission to develop new cancer drugs for patients with high unmet clinical needs. Our collaboration with Innolake is another great opportunity to develop innovative cancer drugs globally, robustly and at speed to serve our communities."

Mingde Xia, CEO of Innolake, commented: "This partnership is a great validation of our technology and capabilities. Having advanced ILB-3101 from early discovery through to the clinic, we are delighted to collaborate with Ellipses and look forward to bringing this innovative therapy to patients worldwide."

(Press release, Ellipses Pharma, JAN 22, 2026, View Source [SID1234662177])